(R)-1-(6-Methoxy-pyrimidin-4-yl)-pyrrolidin-3-ol, 95.0%, 250mg

2-Bromo-4-nitroaniline, 91.0%, 10g

2-FLUOROPYRIMIDIN-4-AMINE, 95.0%, 500mg

4-(2-Benzothiazolyl)-1-chlorobenzene, 98.0%, 1g

Methyl 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate, 95.0%, 10g

methyl 2-amino-4-pyridin-4-ylthiophene-3-carboxylate, 95.0%, 1g

Volumetric flasks with glass stopper, class A Brown glass, 20 ml, 12/21, 2 Piece(s)

1-(3-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propyl)piperidine, 98%, 100mg

2H-Pyran-2-one, 6-[2-(1,3-benzodioxol-5-yl)ethyl]-5,6-dihydro-4-methoxy-, (6S)-, 90%, 50mg

5(4)-Amino-4(5)-(aminocarbonyl)imidazole Hydrochloride>98.0%(HPLC)(T)25g

4-(2,6-di-tert-butyl-4-((2-((3,5-di-tert-butyl-4-hydroxyphenyl)thio)propan-2-yl)thio)phenoxy)-4-oxobutanoic acid, 98%, 50mg

3-(2-Furyl)-2-(trifluoromethyl)propanoic acid, 1g

(S)-2-Chloro-N-(6-methyl-5-((3-(2-(piperidin-3-ylamino)pyrimidin-4-yl)pyridin-2-yl)oxy)naphthalen-1-yl)benzenesulfonamide, 97%, 5mg